Antibody Drug Conjugates Market Report and Forecast 2025-2034
Description
The global antibody drug conjugates market size was valued at USD 7.96 Billion in 2024, driven by the increasing awareness among government and realizing the potential of antibody drug conjugates across the globe. The market size is anticipated to grow at a CAGR of 17.10% during the forecast period of 2025-2034 to achieve a value of USD 38.59 Billion by 2034.
Antibody Drug Conjugates: Introduction
Antibody-drug conjugates are a cutting-edge therapeutic approach that combines the distinct, high specificity, properties, and anti-tumour activity of monoclonal antibodies (mAbs), which are tumour-specific but insufficiently cytotoxic, with the potent cell-killing activity of highly cytotoxic small molecules that are inappropriate for systemic administration alone. Because these compounds have the ability to deliver highly cytotoxic payloads directly to tumour cells, they can be employed to achieve great lethality towards the targeted cancer cells while sparing healthy cells.
A new form of extremely powerful biopharmaceutical medication known as an "antibody-drug conjugate," or ADC, consists of an antibody coupled to a biologically active drug or cytotoxic substance via a chemical linker. These targeted medicines combine the particular and acute targeting characteristics of antibodies, enabling sensitive differentiation between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs.
Global Antibody Drug Conjugates Market Analysis
The market for antibody drug conjugates has been witnessing significant growth and is expected to keep growing in the coming years as well due to various trends going on in the market currently. Antibody drug conjugates are used in the treatment of cancer but there are some attempts that have been made to expand the application of ADCs to different diseases such as atherosclerosis, bacteremia, and inflammatory diseases. The research to expand the applications is currently in progress and soon will be releasing outcomes, further expected to fuel the market growth.
LegoChem Biosciences is the key player in the market and is a major ADC developer with 25 drug candidates in development, expected to further drive the market growth. Despite, most of its pipeline assets are in the preclinical phase. The most advanced drug by LegoChem Biosciences is in Phase II clinical trials. With the most advanced portfolio, Seagen has five launched products and seven clinical-stage candidates, propelling the global antibody drug conjugates market growth.
Pfizer has announced a major investment of USD 43 billion in cash to acquire ADC pioneer Seagen Inc. The US big pharma was pulled towards four of the approved products of Seagen’s, out of which three ADCs and a small-molecule cancer drug along with other candidates in its pipeline. The expected annual revenue generated out of this purchase is USD 10bn by 2030, further propelling the market growth.
Chief Executive Officer at ImmunoGen, Inc. Enyedy exhibited the company’s partnership with MacroGenics, Inc. The collaborating companies are co-developing IMGC936 as a first-in-class ADAM9-targeting ADC. ADAM9 is a cell surface protein from the ADAM (a disintegrin and metalloproteinase) family of proteases, which has been implicated in cytokine and growth factor shedding and cell migration. It has been shown that ADAM9 is overexpressed in multiple solid tumor types (eg, non-small cell lung cancer, gastric, pancreatic, triple-negative breast and colorectal) and minimally expressed on normal tissue. IMGC936 is being tested in Phase I studies, contributing to the antibody drug conjugates market growth.
Additionally, BioNTech SE has also made and important announcement regarding exclusive license and collaboration agreements with DualityBio for two antibody-drug conjugate assets to develop and commercialize globally (excluding some Asian markets). DualityBio is expected to receive USD 170m, as well as potential development, regulatory and commercial milestone payments for both assets, totaling more than USD 1.5 billion, expected to further escalate the market expansion.
Global Antibody Drug Conjugates Market Segmentations
Antibody Drug Conjugates Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
The market is experiencing significant market growth due to the increasing prevalence of cancer among people globally. The rising incidence of breast cancer worldwide is also contributing to the market growth. The major factors responsible for the growth of the antibody-drug conjugates market include the increasing geriatric population along with the rising research and development activities for the development of innovative treatments. Antibody-drug conjugates are believed to provide the most effective treatments to cancer patients. The lifetime probability of being diagnosed with invasive cancer is slightly higher for men (40.9%) than for women. Higher risk in men for most cancer types is thought to largely reflect greater exposure to carcinogenic environmental and behavioural factors, such as smoking, consuming alcohol, among other factors.
Geographically, North America has the highest cases of cancer, and the increasing number of cancer cases is contributing to the market growth in the region. The presence of some key players of the market aiding the antibody drug conjugates market share in the region.
In total, there will be approximately 1,958,310 new cancer cases, the equivalent of about 5370 cases each day. In addition, there will be about 55,720 new cases of ductal carcinoma in situ in women and 89,070 new cases of melanoma in situ of the skin, further increasing the demand for antibody drug conjugates.
Antibody Drug Conjugates Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Antibody Drug Conjugates: Introduction
Antibody-drug conjugates are a cutting-edge therapeutic approach that combines the distinct, high specificity, properties, and anti-tumour activity of monoclonal antibodies (mAbs), which are tumour-specific but insufficiently cytotoxic, with the potent cell-killing activity of highly cytotoxic small molecules that are inappropriate for systemic administration alone. Because these compounds have the ability to deliver highly cytotoxic payloads directly to tumour cells, they can be employed to achieve great lethality towards the targeted cancer cells while sparing healthy cells.
A new form of extremely powerful biopharmaceutical medication known as an "antibody-drug conjugate," or ADC, consists of an antibody coupled to a biologically active drug or cytotoxic substance via a chemical linker. These targeted medicines combine the particular and acute targeting characteristics of antibodies, enabling sensitive differentiation between healthy and cancer tissues with the cell-killing ability of cytotoxic drugs.
Global Antibody Drug Conjugates Market Analysis
The market for antibody drug conjugates has been witnessing significant growth and is expected to keep growing in the coming years as well due to various trends going on in the market currently. Antibody drug conjugates are used in the treatment of cancer but there are some attempts that have been made to expand the application of ADCs to different diseases such as atherosclerosis, bacteremia, and inflammatory diseases. The research to expand the applications is currently in progress and soon will be releasing outcomes, further expected to fuel the market growth.
LegoChem Biosciences is the key player in the market and is a major ADC developer with 25 drug candidates in development, expected to further drive the market growth. Despite, most of its pipeline assets are in the preclinical phase. The most advanced drug by LegoChem Biosciences is in Phase II clinical trials. With the most advanced portfolio, Seagen has five launched products and seven clinical-stage candidates, propelling the global antibody drug conjugates market growth.
Pfizer has announced a major investment of USD 43 billion in cash to acquire ADC pioneer Seagen Inc. The US big pharma was pulled towards four of the approved products of Seagen’s, out of which three ADCs and a small-molecule cancer drug along with other candidates in its pipeline. The expected annual revenue generated out of this purchase is USD 10bn by 2030, further propelling the market growth.
Chief Executive Officer at ImmunoGen, Inc. Enyedy exhibited the company’s partnership with MacroGenics, Inc. The collaborating companies are co-developing IMGC936 as a first-in-class ADAM9-targeting ADC. ADAM9 is a cell surface protein from the ADAM (a disintegrin and metalloproteinase) family of proteases, which has been implicated in cytokine and growth factor shedding and cell migration. It has been shown that ADAM9 is overexpressed in multiple solid tumor types (eg, non-small cell lung cancer, gastric, pancreatic, triple-negative breast and colorectal) and minimally expressed on normal tissue. IMGC936 is being tested in Phase I studies, contributing to the antibody drug conjugates market growth.
Additionally, BioNTech SE has also made and important announcement regarding exclusive license and collaboration agreements with DualityBio for two antibody-drug conjugate assets to develop and commercialize globally (excluding some Asian markets). DualityBio is expected to receive USD 170m, as well as potential development, regulatory and commercial milestone payments for both assets, totaling more than USD 1.5 billion, expected to further escalate the market expansion.
Global Antibody Drug Conjugates Market Segmentations
Antibody Drug Conjugates Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Product Type
- Adcetris
- Kadcyla
- Other Product Types
- Blood Cancer
- Breast Cancer
- Ovary Cancer
- Lung Cancer
- Skin Cancer
- Brain Tumour
- Other Application
- CD30 Antibodies
- HER2 Antibodies
- Other Target Types
- Hospitals and Specialty Cancer Centers
- Biotechnology and Pharmaceutical Companies
- Other End Users
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The market is experiencing significant market growth due to the increasing prevalence of cancer among people globally. The rising incidence of breast cancer worldwide is also contributing to the market growth. The major factors responsible for the growth of the antibody-drug conjugates market include the increasing geriatric population along with the rising research and development activities for the development of innovative treatments. Antibody-drug conjugates are believed to provide the most effective treatments to cancer patients. The lifetime probability of being diagnosed with invasive cancer is slightly higher for men (40.9%) than for women. Higher risk in men for most cancer types is thought to largely reflect greater exposure to carcinogenic environmental and behavioural factors, such as smoking, consuming alcohol, among other factors.
Geographically, North America has the highest cases of cancer, and the increasing number of cancer cases is contributing to the market growth in the region. The presence of some key players of the market aiding the antibody drug conjugates market share in the region.
In total, there will be approximately 1,958,310 new cancer cases, the equivalent of about 5370 cases each day. In addition, there will be about 55,720 new cases of ductal carcinoma in situ in women and 89,070 new cases of melanoma in situ of the skin, further increasing the demand for antibody drug conjugates.
Antibody Drug Conjugates Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Seagen Inc.
- ImmunoGen Inc.
- Mersana Therapeutics Inc.
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Sorrento Therapeutics Inc.
- Oxford BioTherapeutics Ltd
- AbbVie Inc.
- Takeda Pharmaceutical Company Ltd
- AstraZeneca PLC
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Antibody Drug Conjugates Market Overview
- 3.1 Global Antibody Drug Conjugates Market Historical Value (2018-2024)
- 3.2 Global Antibody Drug Conjugates Market Forecast Value (2025-2034)
- 4 Global Antibody Drug Conjugates Market Landscape
- 4.1 Global Antibody Drug Conjugates: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Antibody Drug Conjugates: Product Landscape
- 4.2.1 Analysis by Isotope
- 4.2.2 Analysis by Technology
- 4.2.3 Analysis by Applications
- 5 Global Antibody Drug Conjugates Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Antibody Drug Conjugates Market Segmentation
- 6.1 Global Antibody Drug Conjugates Market by Product Type
- 6.1.1 Market Overview
- 6.1.2 Adcetris
- 6.1.3 Kadcyla
- 6.1.4 Other Product Types
- 6.2 Global Antibody Drug Conjugates Market by Applications
- 6.2.1 Market Overview
- 6.2.2 Blood Cancer
- 6.2.3 Breast Cancer
- 6.2.4 Ovary Cancer
- 6.2.5 Lung Cancer
- 6.2.6 Skin Cancer
- 6.2.7 Brain Tumor
- 6.2.8 Other Application
- 6.3 Global Antibody Drug Conjugates Market by Target Type
- 6.3.1 Market Overview
- 6.3.2 CD30 Antibodies
- 6.3.3 HER2 Antibodies
- 6.3.4 Other Target Types
- 6.4 Global Antibody Drug Conjugates Market by End User
- 6.4.1 Market Overview
- 6.4.2 Hospitals and Specialty Cancer Centers
- 6.4.3 Biotechnology and Pharmaceutical Companies
- 6.4.4 Other End Users
- 6.5 Global Antibody Drug Conjugates Market by Region
- 6.5.1 Market Overview
- 6.5.2 North America
- 6.5.3 Europe
- 6.5.4 Asia Pacific
- 6.5.5 Latin America
- 6.5.6 Middle East and Africa
- 7 North America Antibody Drug Conjugates Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Antibody Drug Conjugates Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Antibody Drug Conjugates Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Antibody Drug Conjugates Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Antibody Drug Conjugates Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Regulatory Framework
- 12.1 Regulatory Overview
- 12.1.1 US FDA
- 12.1.2 EU EMA
- 12.1.3 INDIA CDSCO
- 12.1.4 JAPAN PMDA
- 12.1.5 Others
- 13 Patent Analysis
- 13.1 Analysis by Type of Patent
- 13.2 Analysis by Publication year
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Patent Age
- 13.5 Analysis by CPC Analysis
- 13.6 Analysis by Patent Valuation
- 13.7 Analysis by Key Players
- 14 Grants Analysis
- 14.1 Analysis by year
- 14.2 Analysis by Amount Awarded
- 14.3 Analysis by Issuing Authority
- 14.4 Analysis by Grant Application
- 14.5 Analysis by Funding Institute
- 14.6 Analysis by NIH Departments
- 14.7 Analysis by Recipient Organization
- 15 Clinical Trials Analysis
- 15.1 Analysis by Trial Registration Year
- 15.2 Analysis by Trial Status
- 15.3 Analysis by Trial Phase
- 15.4 Analysis by Therapeutic Area
- 15.5 Analysis by Geography
- 16 Funding and Investment Analysis
- 16.1 Analysis by Funding Instances
- 16.2 Analysis by Type of Funding
- 16.3 Analysis by Funding Amount
- 16.4 Analysis by Leading Players
- 16.5 Analysis by Leading Investors
- 16.6 Analysis by Geography
- 17 Partnership and Collaborations Analysis
- 17.1 Analysis by Partnership Instances
- 17.2 Analysis by Type of Partnership
- 17.3 Analysis by Leading Players
- 17.4 Analysis by Geography
- 18 Supplier Landscape
- 18.1 Seagen Inc.
- 18.1.1 Financial Analysis
- 18.1.2 Product Portfolio
- 18.1.3 Demographic Reach and Achievements
- 18.1.4 Mergers and Acquisitions
- 18.1.5 Certifications
- 18.2 ImmunoGen Inc.
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Mergers and Acquisitions
- 18.2.5 Certifications
- 18.3 Mersana Therapeutics Inc.
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Mergers and Acquisitions
- 18.3.5 Certifications
- 18.4 Pfizer Inc.
- 18.4.1 Financial Analysis
- 18.4.2 Product Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Mergers and Acquisitions
- 18.4.5 Certifications
- 18.5 F. Hoffmann-La Roche Ltd
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Mergers and Acquisitions
- 18.5.5 Certifications
- 18.6 Sorrento Therapeutics Inc.
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Mergers and Acquisitions
- 18.6.5 Certifications
- 18.7 Oxford BioTherapeutics Ltd
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Mergers and Acquisitions
- 18.7.5 Certifications
- 18.8 AbbVie Inc.
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Mergers and Acquisitions
- 18.8.5 Certifications
- 18.9 Takeda Pharmaceutical Company Ltd
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Mergers and Acquisitions
- 18.9.5 Certifications
- 18.10 AstraZeneca PLC
- 18.10.1 Financial Analysis
- 18.10.2 Product Portfolio
- 18.10.3 Demographic Reach and Achievements
- 18.10.4 Mergers and Acquisitions
- 18.10.5 Certifications
- 19 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 20 Company Competitiveness Analysis (Additional Insight)
- 20.1 Very Small Companies
- 20.2 Small Companies
- 20.3 Mid-Sized Companies
- 20.4 Large Companies
- 20.5 Very Large Companies
- 21 Payment Methods (Additional Insight)
- 21.1 Government Funded
- 21.2 Private Insurance
- 21.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
